Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Waterloo

$25,000.00

Quantitative biochemical response profiling as a methodology for comparing biosimilar compounds

FY 2015-16

Summary
A major market area for biotechnology products is monoclonal antibodies, which have applications as diagnostic tools, pharmaceuticals and molecular biology reagents. However, methods for producing monoclonal antibodies do not typically produce a single type of biomolecule, but instead produce an assemblage of closely related biomolecules that can have differences in glycosylation patterns and other secondary features. This may result in subtle differences in biological effects of the monoclonal antibody. Developing methods for identifying potential variations of biological effects of monoclonal antibodies is therefore of considerable practical importance. One area that is potentially impacted by these variations is subsequent-entry pharmaceuticals including biosimilars and interchangeable biologics, which are analogs of established pharmaceuticals. To demonstrate that these compounds are equivalent to originator biologics, manufacturers must satisfy regulatory requirements that involve rigourous tests of statistical equivalence. This can be challenging for complex biomolecules such as monoclonal antibodies, as secondary features including glycosylation are often variable for both the originator and biosimilar compound. Novel approaches are therefore needed to meet statistical requirements of equivalency, especially where potency and immunological function are influenced by glycans. This project will develop quantitative methodology, through the use of high-throughput expression analysis, to assess and compare biochemical effects of biosimilars and originator compounds. The proposed study will investigate the effectiveness of high-throughput gene and protein expression analysis as tools to compare the biological effects of biosimilars with corresponding originator biologics. The specific target used as a model within this project is Trastuzumab (Herceptin), a monoclonal antibody that interferes with the HER2/neu receptor, which is unregulated in certain cancers. Responses to trastuzumab biosimilars will be investigated, which will either show equivalence of effect within appropriate margins, or may reveal unexpected effects that could point to novel biological impacts.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
488291-2015
Name nom
McConkey, Brendan
Department département
Biology
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5004
Research subject group en
Genetics
Research subject group fr
Génétique
Research subject en
Genome analysis
Research subject fr
Analyse du génome
Partie
1
Nb partie
1
Application title
Quantitative biochemical response profiling as a methodology for comparing biosimilar compounds
Keyword
NSERC
Application summary
A major market area for biotechnology products is monoclonal antibodies, which have applications as diagnostic tools, pharmaceuticals and molecular biology reagents. However, methods for producing monoclonal antibodies do not typically produce a single type of biomolecule, but instead produce an assemblage of closely related biomolecules that can have differences in glycosylation patterns and other secondary features. This may result in subtle differences in biological effects of the monoclonal antibody. Developing methods for identifying potential variations of biological effects of monoclonal antibodies is therefore of considerable practical importance. One area that is potentially impacted by these variations is subsequent-entry pharmaceuticals including biosimilars and interchangeable biologics, which are analogs of established pharmaceuticals. To demonstrate that these compounds are equivalent to originator biologics, manufacturers must satisfy regulatory requirements that involve rigourous tests of statistical equivalence. This can be challenging for complex biomolecules such as monoclonal antibodies, as secondary features including glycosylation are often variable for both the originator and biosimilar compound. Novel approaches are therefore needed to meet statistical requirements of equivalency, especially where potency and immunological function are influenced by glycans. This project will develop quantitative methodology, through the use of high-throughput expression analysis, to assess and compare biochemical effects of biosimilars and originator compounds. The proposed study will investigate the effectiveness of high-throughput gene and protein expression analysis as tools to compare the biological effects of biosimilars with corresponding originator biologics. The specific target used as a model within this project is Trastuzumab (Herceptin), a monoclonal antibody that interferes with the HER2/neu receptor, which is unregulated in certain cancers. Responses to trastuzumab biosimilars will be investigated, which will either show equivalence of effect within appropriate margins, or may reveal unexpected effects that could point to novel biological impacts.